← Back to Search

Other

NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)

Phase 2
Waitlist Available
Research Sponsored by Aptinyx
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up subjects will be followed up to 14 days post-dose

Summary

This trial will test the effects of NYX-458 on mild cognitive impairment, mild dementia, and prodromal or manifest Lewy body dementia.

Eligible Conditions
  • Dementia
  • Lewy Body Dementia
  • Forgetfulness
  • Lewy Body Disease
  • Parkinson's Disease
  • Mild Cognitive Impairment

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~subjects will be followed up to 14 days post-dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and subjects will be followed up to 14 days post-dose for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from baseline dissociative effects, psychosis, and hallucinatory symptoms as measured by the Neuropsychiatric Inventory (NPI-12)
Change from baseline in motor complications as measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 4
Change from baseline in physical examination
+5 more
Secondary study objectives
Change from baseline in the Groton Maze Learning Test
Change from baseline in the Identification Test
Change from baseline in the International Shopping List Test
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NYX-458 30 mgExperimental Treatment1 Intervention
Single oral dose taken daily for 12 weeks.
Group II: PlaceboPlacebo Group1 Intervention
Matching placebo Capsules

Find a Location

Who is running the clinical trial?

CogState Ltd.Industry Sponsor
7 Previous Clinical Trials
314 Total Patients Enrolled
AptinyxLead Sponsor
8 Previous Clinical Trials
1,235 Total Patients Enrolled
Worldwide Clinical TrialsOTHER
65 Previous Clinical Trials
14,761 Total Patients Enrolled
2 Trials studying Dementia
251 Patients Enrolled for Dementia
~16 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top